Biosimilars: State of Clinical and Regulatory Science

by Agnes Victoria Klein, Jian Wang, Brian G. Feagan, Mark Omoto
Published 2018-01-01

A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease

by Mahmoud H Mosli, Othman Al-Harbi, Brian G Feagan, Majid A Almadi
Published 2015-01-01

The role of imaging in determining prognosis for primary sclerosing cholangitis: A systematic review

by Dan Segal, Paul Marotta, Mahmoud Mosli, Guangyong Zou, Brian G Feagan, Bandar Al-Judaibi
Published 2019-01-01

Overview of Subsequent Entry Biologics for the Management of Inflammatory Bowel Disease and Canadian Association of Gastroenterology Position Statement on Subsequent Entry Biologic...

by Shane M Devlin, Brian Bressler, Charles N Bernstein, Richard N Fedorak, Alain Bitton, Harminder Singh, Brian G Feagan
Published 2013-01-01

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis

by Bryan Linggi, Vipul Jairath, Guangyong Zou, Lisa M. Shackelton, Dermot P. B. McGovern, Azucena Salas, Bram Verstockt, Mark S. Silverberg, Shadi Nayeri, Brian G. Feagan, Niels Vande Casteele
Published 2021-09-01

Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis

by Remo Panaccione, Richard N Fedorak, Guy Aumais, Edmond-Jean Bernard, Charles N Bernstein, Alain Bitton, Ken Croitoru, Levinus A Dieleman, Robert Enns, Brian G Feagan, Denis Franchimont, Gordon R Greenberg, Anne-Marie Griffiths, John K Marshall, Pierre Pare, Sunil Patel, Robert Penner, Craig Render, Ernest Seidman, A Hillary Steinhart
Published 2008-01-01